Genome International India Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
- Paid Up Capital ₹ 0.10 M
- Company Age 20 Year, 7 Months
- Last Filing with ROC 31 Mar 2021
- Revenue Growth 6.48%
- Profit Growth -98.02%
- Ebitda -54.42%
- Net Worth 1.08%
- Total Assets 13.02%
About Genome International India
Genome International India Private Limited (GIIPL) is a Private Limited Indian Non-Government Company incorporated in India on 09 July 2004 and has a history of 20 years and seven months. Its registered office is in Kanchipuram, Tamil Nadu, India.
The Corporate was formerly known as Genome International Private Limited. The Company is engaged in the Information Technology Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Nathambal and Periannan Senapathy serve as directors at the Company.
Company Details
-
Location
Kanchipuram, Tamil Nadu, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U73100TN2004PTC053684
-
Company No.
053684
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
09 Jul 2004
-
Date of AGM
30 Nov 2021
-
Date of Balance Sheet
31 Mar 2021
-
Listing Status
Unlisted
-
ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Genome International India?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nathambal
|
Director | 01-Sep-2004 | Current |
|
Periannan Senapathy
|
Director | 09-Jul-2004 | Current |
Financial Performance of Genome International India.
Genome International India Private Limited, for the financial year ended 2018, experienced modest growth in revenue, with a 6.48% increase. The company also saw a substantial fall in profitability, with a 98.02% decrease in profit. The company's net worth moved up by a moderate rise of 1.08%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Genome International India?
In 2018, Genome International India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Velalar Mills Private LimitedPeriannan Senapathy is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Genome International India?
Genome International India has a workforce of 30 employees as of Mar 27, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Genome International India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Genome International India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
